NCT05118737View on ClinicalTrials.gov

Adding Colchicine to Tocilizumab in Patients With Severe COVID-19 Pneumonia.

EARLY_PHASE1UnknownINTERVENTIONAL
Enrollment

230

Participants

Timeline

Start Date

October 1, 2021

Primary Completion Date

April 30, 2022

Study Completion Date

August 30, 2022

Conditions
COVID-19 Pneumonia
Interventions
DRUG

Colchicine

colchicine to be used among COVID-19 patients admitted to HMGH, CH, and CDC and already received tocilizumab

Trial Locations (1)

3050

RECRUITING

Alaa Rahal, Doha

Sponsors
All Listed Sponsors
lead

Hamad Medical Corporation

INDUSTRY

NCT05118737 - Adding Colchicine to Tocilizumab in Patients With Severe COVID-19 Pneumonia. | Biotech Hunter | Biotech Hunter